Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Decitabine + Inecalcitol|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Decitabine||Dacogen||5-aza-2-deoxycytidine||DNMT inhibitor (Pan) 5||Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov).|
|Inecalcitol||ICC|TX-522|TX522||Inecalcitol (X-522) is an analog of calcitriol that binds to and activates the Vitamin D3 receptor, potentially resulting in increased apoptosis and decreased growth of tumor cells (PMID: 21732345, PMID: 23388458).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02802267||Phase II||Decitabine + Inecalcitol Decitabine||Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy||Unknown status|